| Predicted Trait | |
| Reported Trait | Breast carcinoma |
| Mapped Trait(s) | breast carcinoma (EFO_0000305) |
| Score Construction | |
| PGS Name | LDpred2 |
| Development Method | |
| Name | LDpred2 |
| Parameters | LDpred2 estimates the posterior mean effect size of each SNP, while accounting for the effect estimates of other correlated SNPs. This method employs a point-normal prior, selecting only a subset of SNPs with non-zero estimated effects for inclusion in the PGS. LDpred2 involves three key hyperparameters: the fraction of causal SNPs, SNP-based heritability, and sparsity (True or False). Settings were selected based on their ability to produce the highest receiver operating characteristic curve (AUC) in the UKB tuning data, with final settings of 0.01 for the fraction of causal SNPs, 0.0861 for SNP-based heritability, and no sparsity, yielding an AUC of 0.65 in the UKB tuning data. |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 961,355 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000771 |
| Citation (link to publication) | Tanha HM et al. Eur J Hum Genet (2026) |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST010098 Europe PMC: 32424353 |
247,173 individuals | European | BCAC |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) | Phenotype Definitions & Methods | Age of Study Participants | Participant Follow-up Time | Additional Ancestry Description | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| — | [ ,
0.0 % Male samples |
European | UKB | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174). | — | PC1-PC4 values ±3s.d. from the 1000G European cluster | — |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM023138 | PSS012140| European Ancestry| 212,360 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.663 [0.654, 0.673] | — | - | — |
| PPM023143 | PSS012138| European Ancestry| 8,291 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.658 [0.619, 0.697] | — | - | — |
| PPM023148 | PSS012137| European Ancestry| 2,654 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.683 [0.644, 0.722] | — | - | — |
| PPM023153 | PSS012139| African Ancestry| 4,427 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.592 [0.479, 0.705] | — | - | — |
| PPM023163 | PSS012140| European Ancestry| 212,360 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.667 [0.657, 0.676] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
| PPM023168 | PSS012138| European Ancestry| 8,291 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.656 [0.616, 0.696] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
| PPM023178 | PSS012139| African Ancestry| 4,427 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.59 [0.488, 0.691] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
| PPM023183 | PSS012141| South Asian Ancestry| 4,435 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.642 [0.558, 0.727] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
| PPM023158 | PSS012141| South Asian Ancestry| 4,435 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.67 [0.59, 0.75] | — | - | — |
| PPM023173 | PSS012137| European Ancestry| 2,654 individuals |
PGP000771 | Tanha HM et al. Eur J Hum Genet (2026) |
Reported Trait: Breast Carcinoma | — | AUROC: 0.676 [0.636, 0.715] | — | Age-specific absolute risk adjusted by PGS relative risk | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS012137 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
European | PC1-PC4 values ±3s.d. from the 1000G European cluster | MCCS | MCCS had a case/sub-cohort design, leading to a higher proportion of cases | |
| PSS012138 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
European | PC1-PC4 values ±3s.d. from the 1000G European cluster | QSKIN | — | |
| PSS012139 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
African American or Afro-Caribbean | AFR individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — | |
| PSS012140 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
European | EUR individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — | |
| PSS012141 | Linked cancer registry records were used to identify females diagnosed with invasive breast cancer (ICD-10 code: C50; ICD-9 code: 174) within five years of prediction baseline. | — | [ ,
0.0 % Male samples |
South Asian | SAS individuals were identified by PC1-PC4 from 1000G and k-means clustering. | UKB | — |